


Inventor(s): Darrell R. Anderson et al.
 Appln. No.: 08 | 921,060
 Series Code ↑ | Serial No. ↑

Group Art Unit: 1644
 Examiner: R. Schwadron
 Atty. Dkt. P 0275463
 M# | Client Ref

Filed: August 29, 1997

Hon. Commissioner of Patents
 Washington, D.C. 20231

Appln. Title: Combined Therapy of B Cell Lymphoma
 with Anti-CD20 Antibody and
 Chemotherapeutic Agents



RECEIVED

Sir:

REPLY/AMENDMENT/LETTER

Date: April 24, 2001

APR 27 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

TECH CENTER 1600/2900

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
 B. ☒ Withdrawn
 C. ☐ made herewith
 D. ☐ made previously

For B & C
 See **Required
 Separate Paper
 (Pat-256)**

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	20	**minus 20	0	x \$18/\$9 = + \$0	103/203
3. Independent Claims	2	***minus 3	0	x \$80/\$40 = + \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add				+ \$270/\$135 = + \$0	104/204
5. Original due Date: January 24, 2001		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$390/\$195 = (3 mos) \$890/\$445 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1390/\$695= (Usable only for 30 day/1mo.OA --- 5 mos) \$1890/\$945=	+ \$890		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$890		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55		+ \$0 148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180		+ \$0 126
or if Rule 97(d) Request add			+ \$180		+ \$0 126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$710/355		+ \$0 146/246
12. No. of additional inventions for examination per Rule 129(b).....			x \$710/355 ea		+ \$0 149/249
13. Request for Continued Examination (RCE)			+ \$710/355		+ \$0 1179/1279
14. Petition fee for			+ \$0		
15. TOTAL FEE ENCLOSED =			\$890		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 | 0275463

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Bonnie D. Weiss

Sig:

Reg. No. 43,255

Fax: (202) 822-0944

Tel: (202) 861-3661

1100 New York Avenue, NW
 Ninth Floor
 Washington, DC 20005-3918
 Tel: (202) 861-3000
 Atty/Sec: BDW/kmh

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

29/E
5/2/01
RECEIVED
APR 27 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Application Serial No. 08/921,960

Filed: August 29, 1997



Group Art Unit: 1644

Examiner: R. Schwadron

Title: COMBINED THERAPY OF B CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY AND
CHEMOTHERAPEUTIC AGENTS

* * * * *

REPLY TO OFFICIAL ACTION

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Non-Final Rejection] dated October 24, 2000, please
amend the above-identified application as follows.

In the Title

Please delete the present title and replace it with the following new title:

E1 --COMBINED THERAPY OF B CELL LYMPHOMA WITH ANTI-CD20
ANTIBODY AND CHEMOTHERAPEUTIC AGENTS --

In the Claims

Please enter the following amended claim:

E2 12. (Amended) The method of Claim 11, wherein said chimeric anti-CD20 antibody
is administered once a week at said dosage for about 2 to 10 weeks.

Please enter the following new claims:

E3 --16. A method of treating a human patient suffering from B cell lymphoma
comprising the following steps:

(i) administration of a non-radiolabeled chimeric anti-CD20 antibody which when
administered at any dosage between about 0.4 to about 20.0 mg/kg body

04/25/2001 SSITHIB1 00000130 08921060

01 FC:117

890.00 0P